Healthy Adult Male and Female Volunteers
Conditions
Keywords
bioavailability, pharmacokinetics, safety, tolerability, AVP-923, dextromethorphan, quinidine
Brief summary
This study will be conducted to evaluate the relative bioavailability, pharmacokinetics, safety, and tolerability of AVP-923 (dextromethorphan hydrobromide \[DM\] and quinidine sulfate \[Q\] capsules) when the contents of a capsule are administered in applesauce or via a nasogastric feeding tube, compared with administration of a capsule in healthy, fasting, adult participants.
Detailed description
This is an open-label, single-center, randomized, single-dose, 3-treatment, 3-period, 6-sequence crossover study in healthy adult participants consisting of approximately 7 weeks of treatment. The study population will be limited to extensive metabolizers of cytochrome P450 (CYP) 2D6. Approximately 18 participants will be randomly assigned to 1 of 6 sequences (ABC, ACB, BAC, BCA, CAB, CBA).
Interventions
DRUGAVP-923
capsule
Sponsors
Avanir Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adults, 18 to 65 years of age, inclusive * Willing to sign informed consent form * Cytochrome P450 2D6 genotype that confers extensive metabolizer profile (as per documented phenotype interpretation from local laboratory and approval from Avanir)
Exclusion criteria
* History or presence of significant pulmonary, hepatic, renal, hematologic, allergic, endocrine (including diabetes), immunologic, dermatologic, neurologic (including history or presence of seizures or convulsive disorders), psychiatric disease (including history of suicidal ideation or behavior) or any eating disorder deemed clinically significant by the investigator * History or presence of significant cardiovascular disease, including complete heart block, QT interval corrected for heart rate (QTc) prolongation, and/or torsades de pointes * History or presence of any gastrointestinal (GI) disease or condition that could compromise participant safety or affect the absorption of study drug, including GI ulcers, GI bleeding, esophageal or gastric varices, and dyspepsia requiring regular (i.e., more frequently than once a month) use of acid-reducing drugs * Known hypersensitivity/intolerance to dextromethorphan or quinidine * Participants whom the principal investigator or his delegate deems to be ineligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean apparent elimination rate constant (kel) for the analytes DM, DX, 3-MM, and Q | pre-dose (within 30 minutes prior to dosing) and post-dose (up to 48 hours after drug administration) |
| Mean area under the concentration time curve (AUC) from time 0 to time of last measurable concentration (AUC0-t) for the analytes dextromethorphan (DM), dextrorphan (DX), 3-methoxymorphinan (3-MM), and quinidine (Q) | pre-dose (within 30 minutes prior to dosing) and post-dose (up to 48 hours after drug administration) |
| Mean AUC from time 0 to infinity (AUC0-inf) for the analytes DM, DX, 3-MM, and Q | pre-dose (within 30 minutes prior to dosing) and post-dose (up to 48 hours after drug administration) |
| Mean maximum plasma concentration (Cmax) for the analytes DM, DX, 3-MM, and Q | pre-dose (within 30 minutes prior to dosing) and post-dose (up to 48 hours after drug administration) |
| Mean time to maximum plasma concentration (Tmax) for the analytes DM, DX, 3-MM, and Q | pre-dose (within 30 minutes prior to dosing) and post-dose (up to 48 hours after drug administration) |
| Mean apparent terminal elimination half-life (t1/2) for the analytes DM, DX, 3-MM, and Q | pre-dose (within 30 minutes prior to dosing) and post-dose (up to 48 hours after drug administration) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with any adverse event | 3 weeks | — |
| Number of participants with any clinically significant clinical laboratory evaluation | 3 weeks | Clinical significance will be determined by the Investigator. |
| Number of participants with any clinically significant physical examination evaluation | 3 weeks | Clinical significance will be determined by the Investigator. |
| Number of participants with any clinically significant electrocardiogram evaluation | 3 weeks | Clinical significance will be determined by the Investigator. |
| Number of participants with any clinically significant vital sign value | 3 weeks | Clinical significance will be determined by the Investigator. |
| Number of participants with the indicated score on the Columbia-Suicide Severity Rating Scale (C-SSRS) | 3 weeks | The C-SSRS will be used to prospectively assess suicidal ideation (intensity rated from 1 \[low severity\] to 5 \[high severity\]) and behavior throughout the study. |
Countries
United States
Outcome results
None listed